214 related articles for article (PubMed ID: 30481153)
1. Utilisation of gonadotrophin-releasing hormone (GnRH) analogue to differentiate ovarian from adrenal hyperandrogenism in postmenopausal women.
Bahaeldein E; Brassill MJ
Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 30481153
[TBL] [Abstract][Full Text] [Related]
2. Clinical Case Seminar: Postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis.
Mamoojee Y; Ganguri M; Taylor N; Quinton R
Clin Endocrinol (Oxf); 2018 Jan; 88(1):13-20. PubMed ID: 28980338
[TBL] [Abstract][Full Text] [Related]
3. Ovarian Leydig Cell Tumor and Ovarian Hyperthecosis in a Postmenopausal Woman: A Case Report and Literature Review.
Bužinskienė D; Marčiukaitytė R; Šidlovska E; Rudaitis V
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374301
[TBL] [Abstract][Full Text] [Related]
4. Bilateral Leydig Cell Hyperplasia: A Rare Cause of Postmenopausal Hirsutism.
Pathmanathan S; De Silva SDN; Sumanatilleke M; Lokuhetty D; Ranathunga UVV
Case Rep Endocrinol; 2022; 2022():8804856. PubMed ID: 35190778
[TBL] [Abstract][Full Text] [Related]
5. Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman.
Hirschberg AL
J Clin Endocrinol Metab; 2023 Apr; 108(5):1243-1253. PubMed ID: 36409990
[TBL] [Abstract][Full Text] [Related]
6. Use of a long-acting gonadotrophin-releasing hormone analogue in a postmenopausal woman with hyperandrogenism due to a hilus cell tumour.
Picón MJ; Lara JI; Sarasa JL; Recasens JD; Clouet R; Gonzalo MA; Rovira A
Eur J Endocrinol; 2000 Jun; 142(6):619. PubMed ID: 10822225
[TBL] [Abstract][Full Text] [Related]
7. A Rare Case of Hyperandrogenism Due to Fibrothecoma and Leydig Cell Tumor in a Postmenopausal Woman With Adrenal Adenoma: A Case Report and Literature Review.
Hussain A; Uy E; Marlowe S; Piercy J; Akbar A
Cureus; 2023 Aug; 15(8):e43180. PubMed ID: 37692722
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic pitfalls in ovarian androgen-secreting (Leydig cell) tumours: case series.
Fanta M; Fischerová D; Indrielle-Kelly T; Koliba P; Zdeňková A; Burgetová A; Vrbíková J
J Obstet Gynaecol; 2019 Apr; 39(3):359-364. PubMed ID: 30428740
[TBL] [Abstract][Full Text] [Related]
9. Androgen suppressive effect of GnRH agonist in ovarian hyperthecosis and virilizing tumours.
Pascale MM; Pugeat M; Roberts M; Rousset H; Déchaud H; Dutrieux-Berger N; Tourniaire J
Clin Endocrinol (Oxf); 1994 Nov; 41(5):571-6. PubMed ID: 7828344
[TBL] [Abstract][Full Text] [Related]
10. Is ovarian and adrenal venous catheterization and sampling helpful in the investigation of hyperandrogenic women?
Kaltsas GA; Mukherjee JJ; Kola B; Isidori AM; Hanson JA; Dacie JE; Reznek R; Monson JP; Grossman AB
Clin Endocrinol (Oxf); 2003 Jul; 59(1):34-43. PubMed ID: 12807501
[TBL] [Abstract][Full Text] [Related]
11. Hyperandrogenism in a postmenopausal woman: diagnostic and therapeutic challenges.
Cheng V; Doshi KB; Falcone T; Faiman C
Endocr Pract; 2011; 17(2):e21-5. PubMed ID: 21247854
[TBL] [Abstract][Full Text] [Related]
12. [Sertoli-Leydig cell tumour (arrhenoblastoma) in a patient with polycystic ovary syndrome: clinical, ultrasonographic, hormonal and histopathological evaluation].
Puzigaća S; Prelević G; Svetenović Z; Djuricić S; Kokan Dj; Radivojević U
Srp Arh Celok Lek; 2001; 129 Suppl 1():51-5. PubMed ID: 15637992
[TBL] [Abstract][Full Text] [Related]
13. Postmenopausal hyperandrogenism.
Yoldemir T
Climacteric; 2022 Apr; 25(2):109-117. PubMed ID: 33988479
[TBL] [Abstract][Full Text] [Related]
14. Management of postmenopausal virilization.
Alpañés M; González-Casbas JM; Sánchez J; Pián H; Escobar-Morreale HF
J Clin Endocrinol Metab; 2012 Aug; 97(8):2584-8. PubMed ID: 22669303
[TBL] [Abstract][Full Text] [Related]
15. Postmenopausal Hyperandrogenism Associated With Synchronous Ovarian Brenner Tumor, Bilateral Leydig Cell Tumor, and Adrenal Mass.
Salim M; Dasaraju S; Erickson B; Khalifa M; Burmeister LA
Cureus; 2024 Mar; 16(3):e55334. PubMed ID: 38559537
[TBL] [Abstract][Full Text] [Related]
16. A Case of Ovarian Hyperthecosis in a Postmenopausal Woman.
Yousaf S; Nizar R; John L; Simpson A
JCEM Case Rep; 2023 Nov; 1(6):luad148. PubMed ID: 38077307
[TBL] [Abstract][Full Text] [Related]
17. Gonadotropin-releasing hormone agonist treatment in postmenopausal women with hyperandrogenism of ovarian origin.
Vollaard ES; van Beek AP; Verburg FA; Roos A; Land JA
J Clin Endocrinol Metab; 2011 May; 96(5):1197-201. PubMed ID: 21307133
[TBL] [Abstract][Full Text] [Related]
18. [Hyperandrogenism after menopause: Ovarian or adrenal origin?].
Sarfati J; Moraillon-Bougerolle M; Christin-Maitre S
Gynecol Obstet Fertil Senol; 2022 Oct; 50(10):675-681. PubMed ID: 35609786
[TBL] [Abstract][Full Text] [Related]
19. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
Kaltsas GA; Korbonits M; Isidori AM; Webb JA; Trainer PJ; Monson JP; Besser GM; Grossman AB
Clin Endocrinol (Oxf); 2000 Oct; 53(4):493-500. PubMed ID: 11012575
[TBL] [Abstract][Full Text] [Related]
20. Hyperandrogenism due to ovarian Leydig cell tumour presenting with polycythaemia.
Demir AY; Blok BB; Brinkhuis EA; Oldenburg-Ligtenberg CP
BMJ Case Rep; 2022 Jul; 15(7):. PubMed ID: 35840164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
